Article
c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
The Journal of biological chemistry - 1 Feb 2008
Bellon Steven F, Kaplan-Lefko Paula, Yang Yajing, Zhang Yihong, Moriguchi Jodi, Rex Karen, Johnson Carol W, Rose Paul E, Long Alexander M, O'Connor Anne B, Gu Yan, Coxon Angela, Kim Tae-Seong, Tasker Andrew, Burgess Teresa L, Dussault Isabelle
Abstract excerpt
c-Met is a receptor tyrosine kinase often deregulated in human cancers, thus making it an attractive drug target. One mechanism by which c-Met deregulation leads to cancer is through gain-of-function mutations. Therefore, small molecules capable of targeting these mutations could offer therapeutic benefits for affected patients. SU11274 was recently described and reported to inhibit the activity of the wild-type...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.